$ONCR

Oncorus Inc

  • NASDAQ
  • Health Technology
  • Biotechnology

PRICE

$1.26 ▼-2.326%

Last Close

VOLUME

74,024

DAY RANGE

1.25 - 1.37

52 WEEK

0.9827 - 14.57

Join Discuss about ONCR with like-minded investors

profile
@dros #droscrew
recently

+Initiations 3/28: $ALBO $ASND $BBAI $BEP $BTCS $DRCT $GBT $GMED $HTZ NUVA $OBSV $ONCR $RBLX $SPIR $TCB $TCN $U

81 Replies 8 👍 9 🔥

Key Metrics

Market Cap

33.39 M

Beta

0.87

Avg. Volume

514.36 K

Shares Outstanding

25.88 M

Yield

0%

Public Float

0

Next Earnings Date

2022-08-03

Next Dividend Date

Company Information

At Oncorus, the company is focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. Oncorus is advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity to tumor cells. Its lead program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities.

Website:

HQ: ,

Related News